Answers are grounded in this paper and cite their sources.
This analysis compares lymph node dissection efficiency in esophageal cancer, highlighting differences between chemoimmunotherapy and chemoradiotherapy.
Background Esophageal squamous cell carcinoma (ESCC) is an aggressive cancer with poor prognosis, especially in advanced stages. Neoadjuvant chemoradiotherapy (nCRT) combined with surgery is standard treatment, but survival rates remain low. Although neoadjuvant chemoimmunotherapy has shown superior results to nCRT in several studies, it is not yet a first-line treatment in guidelines, making further research necessary. Lymph node dissection (LND) is crucial in treatment, especially with extensive metastasis. The lymph node dissection efficiency index, used in gastric cancer, evaluates the value of LND. This study compares the impact of chemoimmunotherapy and chemoradiotherapy on lymph node metastasis and dissection strategies in ESCC. Methods Clinicopathological were retrieved from the prospective Surgical Esophageal Cancer Patient Registry at West China Hospital, Sichuan University. Lymph node stations were categorized according to the AJCC 8th edition and examined separately. The lymph node dissection efficiency index was determined by multiplying the lymph node metastasis rate at each station by the 3-year survival rate of positive patients at that station. Data analysis was performed to compare the outcomes based on different neoadjuvant treatment regimens and various primary tumor locations. Results A total of 166 eligible patients from January to December 2022 were enrolled. In the NCIT group, higher lymph node metastasis rates were observed at stations 1R (16.2%), 2R (17.6%), 16 (18.2%), and 17 (11.3%), with higher LNDEI values at stations 1R (0.0810), 2R (0.0352), 7 (0.0306), 16 (0.0455), 17 (0.0411), and 20 (0.0385). In the NCRT group, higher metastasis rates occurred at stations 2R (13.9%), 2 L (15%), 8 U (12.5%), 16 (19.1%), 18 (13.6%), and 20 (15.4%), with higher LNDEI values at stations 2 L (0.0500), 16 (0.0424), 17 (0.0566), 18 (0.0453), 19 (0.0909), and 20 (0.0770). Conclusion This study compares the lymph node dissection efficiency index across different neoadjuvant regimens in ESCC patients. It highlights the impact of neoadjuvant chemoimmunotherapy on lymph node metastasis rates and dissection efficiency, offering valuable insights for optimizing lymphadenectomy strategies in locally advanced ESCC patients.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: